Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Niels Wenstedt/BSR Agency via Getty Images

Allocations of Johnson & Johnson's coronavirus vaccine will plummet by 80% next week, according to data released by the Centers for Disease and Control Prevention.

Why it matters: J&J's single-dose shot is viewed as key to U.S. efforts to vaccinate enough Americans to reach herd immunity as soon as possible. A spokesperson told the Wall Street Journal that J&J is still aiming to meet its goal of delivering 100 million doses by June.

By the numbers: 4.9 million J&J doses were allocated to states, territories and federal agencies this week. Next week, that number will plunge to 700,000, according to the CDC.

  • It's unclear what caused the sharp decline, but federal officials have warned that supply will fluctuate week to week, according to the WSJ.
  • The week of March 1 saw 2.8 million doses distributed, while the following two weeks' supply fell to around 400,000 to 500,000 doses per week.

The big picture: Manufacturing challenges have plagued J&J from the start, heightening concerns that the company won't be able to meet its goals of 100 million U.S. doses by mid-year and up to 1 billion by the end of 2021.

Go deeper

Caitlin Owens, author of Vitals
Apr 9, 2021 - Health

America may be close to hitting a vaccine wall

Data: CDC; Cartogram: Andrew Witherspoon/Axios

There are growing signs that parts of the country may be close to meeting demand for the coronavirus vaccine — well before the U.S. has reached herd immunity.

Why it matters: For the last few months, the primary focus of the U.S. has been getting shots to everyone who wants them, as quickly as possible. Soon, that focus will abruptly shift to convincing holdouts to get vaccinated.

Apr 8, 2021 - Podcasts

Biden adviser Atul Gawande on vaccine hesitancy and herd immunity

Nearly one in five American adults is hesitant to get a COVID-19 vaccine, which could make it harder for the country to reach herd immunity. Meanwhile, the virus continues to mutate, with the CDC announcing this week that the British variant is dominant in the U.S.

Axios Re:Cap talks with Dr. Atul Gawande, author and Biden administration adviser, about what vaccine hesitancy means for the U.S. and the world.

Updated 9 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios